drugset

drugset / Trial / NCT00191880

Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder

NCT00191880 ↗

Phase 3 Completed 100 enrolled Eli Lilly and Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Open-label trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 years with Attention- Deficit/Hyperactivity Disorder

Timeline

Start: 2004-05
Primary completion: —
Completion: 2006-06

Publications

Dickson RA, Maki E, Gibbins C, Gutkin SW, Turgay A, Weiss MD. Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies. Child Adolesc Psychiatry Ment Health. 2011 May 11;5:14. doi: 10.1186/1753-2000-5-14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atomoxetine	Other / unclassified	—	—

Indications